Theravance Biopharma, Inc. (NASDAQ:TBPH) Q3 2019 Earnings Conference Call - Final Transcript
Nov 05, 2019 • 05:00 pm ET
Ladies and gentlemen good afternoon. I'd like to welcome everyone to the Theravance Biopharma Conference Call. [Operator Instructions]
And now I would like to turn the call over to Jessica Stitt Vice President Finance and Investor Relations. Please go ahead.
Good afternoon everyone and thank you for joining our conference call and webcast to discuss our third quarter 2019 financial results and outlook. Joining us are Rick Winningham Chief Executive Officer Andrew Hindman Chief Financial Officer Brett Haumann Chief Medical Officer and Frank Pasqualone Chief Commercial Operations Officer. Following some prepared remarks we will open the call for questions. A copy of the press release and the slides accompanying this call can be downloaded from our website or you can call Investor Relations at  808-4045 and we'll be happy to assist you. As always I will remind you that this conference call will contain forward-looking statements which involve certain risks and uncertainties including statements about our product pipeline expected benefits of our products the anticipated timing of trial results and regulatory filings and expected financial results. Information concerning factors that could cause results to differ materially from our forward-looking statements is described further in the company's filings with the SEC.
And now I would direct your attention to slide three and hand the call to Rick.
Rick E Winningham
Thanks Jessica. Good afternoon everyone and thank you for joining us. As we approach the end of 2019 a critical year of progress for Theravance Biopharma we believe that our organ-selective focus and research translational science and development has generated a portfolio of product candidates that have the potential to transform the treatment of serious chronic diseases. As we prepare to turn the corner into 2020 it's an exciting time for our company with important value creating milestones expected across our key programs. We have generated a compelling body of evidence attesting to the therapeutic value of organ-selective medicines. These organ-selective medicines are directed at biological targets that cannot be fully leveraged systemically without incurring serious dose-limiting toxicities. We've demonstrated the potential to maximize the value of proven and potent biology to achieve greater efficacy safety and enhanced outcomes for patients. Over the years we've honed our ability to engineer and optimize drug properties that allow for precise organ selectivity to target the site of inflammation and avoid systemic liabilities. Starting with our early work with GSK on lung-specific compounds including components of BREO Anoro and TRELEGY we enhanced and applied our know how to the discovery and development of YUPELRI our once-daily nebulized long-acting muscarinic antagonist or LAMA approved for the maintenance treatment of COPD partnered with Mylan.
Ans our inhaled pan-JAK inhibitor TD-8236 in development for inflammatory lung diseases which has shown encouraging early data in healthy volunteers and mild asthmatics. We further translated our design insights to be able to deliver drugs into the intestinal tract such that today we're advancing 2 gut-selective programs in partnership with Janssen our pan-JAK inhibitor TD1473 and our irreversible JAK3 inhibitor TD5202 both in clinical